Prostate-specific membrane antigen PET/CT cost-effective versus conventional imaging

Reuters Health - 28/12/2020 - Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) provides better accuracy than conventional imaging at a lower cost, researchers in Australia say. "This result was not surprising, given the greater accuracy of PSMA-PET/CT and the reduction in time involved for scan acquisition," Dr. Richard De Abreu Lourenco of the University of Technology Sydney told Reuters Health by email. "This is an important finding that is applicable elsewhere, (given) that the same radiotracer has recently been approved by the FDA," he said. "While healthcare costs vary between countries, the findings of improved accuracy and shorter time to acquisition are transferable." For their cost-effectiveness analysis, published in European Urology, Dr. De Abreu Lorenco and colleagues analyzed data from the proPSMA study, which included 302 men with high-risk prostate cancer randomized to conventional imaging or 6...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 12 December, 20208 January, 2021